İstanbul escort bayan sivas escort samsun escort bayan sakarya escort Muğla escort Mersin escort Escort malatya Escort konya Kocaeli Escort Kayseri Escort izmir escort bayan hatay bayan escort antep Escort bayan eskişehir escort bayan erzurum escort bayan elazığ escort diyarbakır escort escort bayan Çanakkale Bursa Escort bayan Balıkesir escort aydın Escort Antalya Escort ankara bayan escort Adana Escort bayan

63.1 F
San Diego
Sunday, May 19, 2024
-Advertisement-

Inhibrx Files for Nearly $75M IPO

La Jolla-based Inhibrx on June 3 filed for a $74.75 million initial public offering to advance three cancer drugs in clinical trials and other programs.

The IPO follows a recent $40 million investment from Viking Global Investors. The $40 million would convert into shares of Inhibrx stock at 90 percent of the IPO share price, according to U.S. Securities and Exchange Commission paperwork.

Protein engineering underlies the company’s approach, with three drug candidates in phase 1 clinical trials, and two preclinical programs set to enter clinical trials later this year.

One of its drug candidates, Inbrx-103, has been licensed to pharmaceutical Celgene.

CEO Mark Lappe co-founded the company. Previously he was the managing partner of Efficacy Biotech Fund.

Slipping into biotech speak, Inhibrx pitched its sdAb platform as superior to current monoclonal antibody and fusion protein approaches.

-Advertisement-

Featured Articles

Hair Today, Hair Tomorrow

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-